RPL15 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
What is RPL15 and what is its primary cellular function?
RPL15 (Ribosomal Protein L15) is a component of the 60S large ribosomal subunit. It plays a crucial role in the ribosome, which is a large ribonucleoprotein complex responsible for protein synthesis in cells. Functionally, RPL15 contributes to the structural integrity of the ribosome and participates in the translation process. The protein has a calculated molecular weight of approximately 24 kDa, though it typically appears around 27 kDa in Western blot analysis due to post-translational modifications . RPL15 is evolutionarily conserved across mammalian species, indicating its fundamental importance in cellular protein synthesis machinery.
What species reactivity can be expected with commercially available RPL15 antibodies?
Most commercially available RPL15 antibodies demonstrate cross-reactivity with human, mouse, and rat samples . Specific antibodies like Proteintech's 16740-1-AP have been validated for these three species, while published literature also indicates potential reactivity with pig samples . When selecting an RPL15 antibody for your research, it's important to verify the specific reactivity data for your target species, as this can vary between manufacturers and individual antibody clones. For example, Boster Bio's Anti-RPL15 Antibody (A07136-1) specifically highlights reactivity with human, mouse, and rat samples, making it suitable for comparative studies across these mammalian models .
What are the validated applications for RPL15 antibodies in research?
RPL15 antibodies have been validated for multiple experimental applications. Primary applications include Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)/Immunocytochemistry (ICC), and ELISA . According to validation data from Proteintech, their RPL15 antibody (16740-1-AP) has been successfully used in published research for WB in at least four publications and for IF in one publication . The antibody has been positively validated in Western blot analysis using multiple cell lines including COLO 320, HeLa, K-562, and SGC-7901 cells, as well as in mouse brain tissue . For IHC applications, positive detection has been confirmed in human colon tissue with appropriate antigen retrieval methods .
What are the recommended dilution ratios for different experimental applications?
Optimal dilution ratios vary depending on the specific application and the antibody source. Based on the search results, the following dilutions are recommended:
It's important to note that these are starting recommendations, and the optimal dilution should be determined experimentally for each specific research context. Proteintech specifically mentions that their dilution recommendations are sample-dependent and should be titrated in each testing system to obtain optimal results .
What antigen retrieval methods are recommended for RPL15 immunohistochemistry?
For immunohistochemical detection of RPL15, specific antigen retrieval methods have been validated. Proteintech recommends using TE buffer at pH 9.0 for optimal antigen retrieval with their RPL15 antibody (16740-1-AP) . Alternatively, they suggest that citrate buffer at pH 6.0 may also be effective for antigen retrieval, providing researchers with options depending on their specific tissue samples and protocols . The validation data from Proteintech shows successful IHC results in human colon tissue using these retrieval conditions . Proper antigen retrieval is critical for exposing the epitopes recognized by the RPL15 antibody, particularly in formalin-fixed, paraffin-embedded tissues where protein cross-linking can mask antigenic sites.
How should samples be prepared for optimal RPL15 detection?
For Western blot applications, whole cell lysates have been successfully used for RPL15 detection. The search results indicate that H1299 whole cell lysate at 30 μg loading produced clear results with Abcam's anti-RPL15 antibody (ab155802) at 1/1000 dilution on 12% SDS-PAGE . For IHC applications, paraffin-embedded tissue sections have been successfully used with appropriate antigen retrieval as described above . Abcam's antibody specifically demonstrated good results in paraffin-embedded normal colon tissue at a 1/500 dilution . For immunofluorescence studies, HeLa cells have been validated as suitable samples for RPL15 detection . When preparing samples, it's important to include appropriate positive controls, such as the cell lines mentioned in the validation data (COLO 320, HeLa, K-562, SGC-7901), depending on your experimental design .
What is known about RPL15 expression in cancer research?
Research suggests that RPL15 overexpression is associated with cell proliferation in gastric cancer . A study published in BMC Cancer (2006) specifically explored this relationship, indicating that RPL15 may play a role beyond its canonical function in ribosomal assembly and protein synthesis . This implies that RPL15 could potentially serve as a biomarker or therapeutic target in certain cancer contexts. The connection between ribosomal proteins and cancer has been an emerging area of research, with alterations in ribosomal protein expression potentially contributing to tumorigenesis through mechanisms related to protein synthesis dysregulation, cell cycle control, or extraribosomal functions. When designing cancer-related studies involving RPL15, researchers should consider both its ribosomal and potential extraribosomal functions.
What protein-protein interactions involving RPL15 have been documented?
A notable protein interaction was reported in DNA and Cell Biology (2011), describing "A novel interaction between interferon-inducible protein p56 and ribosomal protein L15 in gastric cancer cells" . This interaction suggests that RPL15 may participate in cellular pathways beyond its primary role in protein synthesis, potentially including immune response regulation given the involvement of an interferon-inducible protein. Understanding such interactions is crucial for researchers investigating the broader functional implications of RPL15 in cellular signaling networks, especially in disease contexts like cancer. This documented interaction provides a starting point for researchers interested in exploring the potential extraribosomal functions of RPL15 and how these might contribute to disease pathogenesis or cellular homeostasis.
How can researchers differentiate between specific and non-specific binding when using RPL15 antibodies?
To ensure specific detection and minimize non-specific binding, researchers should implement rigorous controls and optimization steps. First, include appropriate positive controls where RPL15 is known to be expressed, such as validated cell lines like HeLa, K-562, or COLO 320 . Second, implement negative controls by using secondary antibody alone, isotype controls, or samples where RPL15 expression has been knocked down. Third, validate observed bands on Western blots against the expected molecular weight (calculated: 24 kDa; observed: approximately 27 kDa) . Additionally, perform antibody validation by comparing results from multiple antibodies targeting different epitopes of RPL15 when possible. Finally, carefully optimize blocking conditions, antibody dilutions, and incubation times to reduce background and non-specific binding. For particularly challenging tissues or applications, pre-absorption of the antibody with the immunizing peptide (where available) can help confirm specificity.
What are the challenges in detecting RPL15 across different experimental systems?
Detecting RPL15 can present several challenges. First, as a ribosomal protein, RPL15 is likely to be widely expressed across different cell types, which may complicate comparative expression studies. Second, the observed molecular weight (27 kDa) differs from the calculated weight (24 kDa) , potentially due to post-translational modifications, which may vary across experimental systems or physiological conditions. Third, effective detection in fixed tissues requires specific antigen retrieval methods, with different buffers (TE buffer pH 9.0 or citrate buffer pH 6.0) recommended depending on the sample preparation . Additionally, the high conservation of ribosomal proteins across species can present challenges for developing species-specific antibodies. Finally, when studying RPL15 in complex with other ribosomal components, protein-protein interactions may mask epitopes, requiring optimization of sample preparation methods to ensure detection accessibility.
How can researchers validate the specificity of RPL15 antibodies?
To validate RPL15 antibody specificity, researchers should implement multiple complementary approaches. First, verify the correct molecular weight band (expected around 27 kDa) in Western blot applications . Second, compare staining patterns across multiple validated antibodies targeting different RPL15 epitopes. Third, perform knockdown or knockout experiments (using siRNA or CRISPR) to confirm signal reduction or elimination. Fourth, consider peptide competition assays where the immunizing peptide is used to block antibody binding, which should eliminate specific signals. For the Boster Bio antibody (A07136-1), the immunizing peptide was derived from human RPL15 (amino acid range: 41-90), and blocking peptides can be purchased for validation purposes . Finally, cross-validate results using orthogonal methods such as mass spectrometry or RNA expression analysis to confirm that detected signals correlate with RPL15 expression levels.
What positive and negative controls should be used in RPL15 antibody experiments?
For positive controls, use samples with confirmed RPL15 expression. Based on validation data, appropriate positive controls include:
-
Cell lines: COLO 320, HeLa, K-562, and SGC-7901 cells for Western blot
-
Tissues: Human colon tissue for IHC and mouse brain tissue for Western blot
For negative controls, consider:
-
Secondary antibody only controls to assess non-specific binding
-
Isotype controls using non-specific IgG of the same species as the primary antibody
-
RPL15-depleted samples (using siRNA knockdown or CRISPR knockout where feasible)
-
For tissues, consider using tissues known to have low or no expression of RPL15
-
Pre-absorption controls using the immunizing peptide to block specific binding sites
Using these controls systematically helps establish the reliability of experimental results and aids in distinguishing specific from non-specific signals.
How should researchers address inconsistent results when using RPL15 antibodies?
When encountering inconsistent results with RPL15 antibodies, systematically troubleshoot potential issues:
-
Antibody quality: Check antibody age, storage conditions, and freeze-thaw cycles. RPL15 antibodies should be stored at -20°C for long-term storage and at 4°C for up to one month for frequent use .
-
Protocol optimization: Adjust key parameters including:
-
Sample preparation: Ensure proper cell/tissue lysis, protein denaturation, and loading consistency. For Western blot, the validated loading amount is around 30 μg of whole cell lysate .
-
Cross-validation: Compare results using an alternative RPL15 antibody targeting a different epitope, or utilize orthogonal detection methods.
-
Experimental controls: Include appropriate positive controls (e.g., HeLa cells, human colon tissue) and negative controls in each experiment .
-
Reproducibility: Repeat experiments multiple times to distinguish between technical variability and true biological differences.
Document all troubleshooting steps and outcomes systematically to identify the source of inconsistency and establish reliable experimental conditions.
What are the critical factors for maintaining RPL15 antibody performance over time?
To maintain optimal RPL15 antibody performance over time, several critical factors should be considered:
Following these guidelines will help maintain antibody integrity and ensure reproducible experimental results across extended research timelines.
How is RPL15 being studied in cancer research beyond gastric cancer?
While the search results specifically highlight RPL15's role in gastric cancer , the antibodies have been validated in multiple cell lines including COLO 320 (colorectal adenocarcinoma) and K-562 (chronic myelogenous leukemia) , suggesting broader applications in cancer research. Researchers investigating RPL15 in other cancer types should consider both its canonical ribosomal function and potential extraribosomal roles. Given that ribosomal biogenesis and protein synthesis are frequently dysregulated in cancer, RPL15 may serve as a biomarker or therapeutic target across multiple cancer types. Future research directions could include systematic expression analyses across cancer tissue panels, correlation studies with clinical outcomes, and mechanistic investigations into how RPL15 contributes to cancer cell proliferation, survival, or response to therapy.
How can researchers study the interaction between interferon-inducible protein p56 and RPL15?
Building on the documented interaction between interferon-inducible protein p56 and RPL15 in gastric cancer cells , researchers can employ several strategies to further characterize this interaction. First, co-immunoprecipitation experiments using validated RPL15 antibodies can confirm and analyze the interaction under various conditions, such as before and after interferon stimulation. Second, proximity ligation assays can visualize and quantify the interaction in situ within intact cells. Third, domain mapping through deletion mutants can identify the specific regions of RPL15 and p56 responsible for the interaction. Fourth, functional studies comparing wild-type cells with those expressing interaction-deficient mutants can reveal the biological significance of the interaction. Finally, structural biology approaches like X-ray crystallography or cryo-EM can provide atomic-level details of the interaction interface. These approaches would help elucidate whether this interaction represents a novel regulatory mechanism linking translation and interferon responses in cancer contexts.
What are the emerging technologies for studying ribosomal proteins like RPL15?
Emerging technologies are revolutionizing the study of ribosomal proteins including RPL15. First, cryo-electron microscopy now enables high-resolution structural analysis of intact ribosomes, allowing visualization of RPL15's position and potential conformational changes during translation. Second, ribosome profiling combined with next-generation sequencing provides genome-wide insights into the impact of RPL15 on translation of specific mRNAs. Third, CRISPR-based technologies enable precise genome editing to create RPL15 variants for structure-function studies. Fourth, live-cell imaging with split fluorescent proteins or FRET sensors can monitor RPL15 dynamics during translation in real time. Fifth, mass spectrometry-based approaches like thermal proteome profiling can identify changes in RPL15 interactions under different conditions. Finally, computational approaches including AlphaFold2 can predict RPL15's structure and interaction interfaces. Integrating these technologies will provide unprecedented insights into RPL15's roles in normal physiology and disease contexts.
